Please find in attachment my weekly compilation of the most important HCV

news around the world.

To order:send a mail to J.Weinbach@lumc.nl

27 05 2002

In this issue:

* Key Scientific Articles:

*

* Genetic changes in hypervariable region 1 as a possible mechanism

for biochemical responders with interferon therapy. Liver. 2002

Apr;22(2):184-5.

*

* Determinants of hepatitis C translational initiation in vitro, in

cultured cells and mice. Mol Ther. 2002 Jun;5(6):676-84.

* Mutation master: profiles of substitutions in hepatitis C virus RNA

of the core, alternate reading frame, and NS2 coding regions. RNA. 2002

May;8(5):557-71.

* Expression of GP73, a resident Golgi membrane protein, in viral and

nonviral liver disease. Hepatology. 2002 Jun;35(6):1431-1440

* Expression of hepatitis C virus proteins induces distinct membrane

alterations including a candidate viral replication complex. J Virol 2002

Jun;76(12):5974-84

* A collaborative screening program for the discovery of inhibitors of

HCV NS2/3 cis-cleaving protease activity. J Biomol Screen. 2002

Apr;7(2):149-54.

*

* Comprehensive Analysis of CD8(+)-T-Cell Responses against Hepatitis

C Virus Reveals Multiple Unpredicted Specificities. J Virol. 2002 Jun

15;76(12):6104-6113

*

* Molecular and Immunological Significance of Chimpanzee Major

Histocompatibility Complex Haplotypes for Hepatitis C Virus Immune Response

and Vaccination Studies. J Virol. 2002 Jun 15;76(12):6093-6103.

Progression of fibrosis in untreated patients with hepatitis C virus

infection. Liver. 2002 Apr;22(2):136-144.

*

*

* General Hepatitis C-related Info:

Cellular Suicide: Apoptotic mechanisms a hallmark of liver cell damage in

viral hepatitis

Hepatocellular Carcinoma: Amended virus kills liver cancer cells, prevents

growth of new ones

Hepatitis C may be transmitted via toothbrushes

Clinical and Virological Features of Chronic Hepatitis C Patients with

Normal ALT Levels

Interferon doses don't cause thyroid disorder in chronic hepatitis C

SciClone Pharmaceuticals (SCLN) Release: ZADAXIN Selectively Stimulates

Immune System-Related Genes Important In The Fight Against Hepatitis C

NicOx SA (NICOX) And Axcan Pharma (AXCA) Sign Co-Development And License

Agreement For NCX1000 In The Treatment Of Chronic Liver Diseases

InterMune Announces Long-Term Follow Up Data From Phase II Study of

Actimmune In IPF Demonstrates Survival Benefit

All the best in your fight against Hepatitis C.

Jerome Weinbach

Project Manager

On behalf of the European HCVacc vaccine research Cluster.

Leiden University Medical Center

Department of Medical Microbiology, E4-P

P.O. Box 9600

2300 RC Leiden

The Netherlands

Tel: 00 31 71 526 66 92

Fax: 00 31 71 525 67 61